U.S. Markets close in 4 hrs 26 mins

Akebia Therapeutics, Inc. (AKBA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.3950-0.0250 (-1.03%)
As of 11:34AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4200
Open2.3600
Bid2.3900 x 1000
Ask2.4000 x 3200
Day's Range2.3100 - 2.4100
52 Week Range2.3100 - 13.7100
Volume3,707,612
Avg. Volume7,040,766
Market Cap343.244M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-3.0630
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.86
  • Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
    PR Newswire

    Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights

    Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020 before the opening of the financial markets.

  • Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined
    PR Newswire

    Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined

    Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evaluated the efficacy and safety of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), versus darbepoetin alfa for the treatment of anemia due to chronic kidney disease (CKD) in adult patients not on dialysis, at American Society of Nephrology Kidney Week 2020 Reimagined (ASN Kidney Week). As previously announced, vadadustat achieved the primary and key secondary efficacy endpoints in each of the two studies in the program, but did not meet the primary safety endpoint. Newly presented pre-specified regional analyses of the PRO2TECT program show vadadustat demonstrated no clinically meaningful increase in cardiovascular risk compared to darbepoetin alfa in analyses of MACE, expanded MACE and all-cause mortality in U.S. patients treated to a target hemoglobin (Hb) range of 10 to 11 g/dL, consistent with U.S. treatment guidelines.

  • The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
    Benzinga

    The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)Amicus Therapeutics, Inc. (NASDAQ: FOLD) Beam Therapeutics Inc (NASDAQ: BEAM) Bio-Rad Laboratories, Inc. (NYSE: BIO) CymaBay Therapeutics Inc (NASDAQ: CBAY) Halozyme Therapeutics, Inc. (NASDAQ: HALO) Immunomedics, Inc. (NASDAQ: IMMU) Kodiak Sciences Inc (NASDAQ: KOD) Nevro Corp (NYSE: NVRO) Praxis Precision Medicines Inc (NASDAQ: PRAX) Repligen Corporation (NASDAQ: RGEN) Replimune Group Inc (NASDAQ: REPL) (priced its common stock offering of 4.69 million shares at $40 apiece.Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) * Artelo Biosciences Inc (NASDAQ: ARTL) * Avenue Therapeutics Inc (NASDAQ: ATXI) * Aziyo Biologics Inc (NASDAQ: AZYO) * DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) * FSD Pharma Inc (NASDAQ: HUGE) * Gilead Sciences, Inc. (NASDAQ: GILD) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) (priced its $15 million worth of common stock offering) * Jaguar Health Inc (NASDAQ: JAGX) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Metacrine Inc (NASDAQ: MTCR) * Rockwell Medical Inc (NASDAQ: RMTI) * Satsuma Pharmaceuticals Inc (NASDAQ: STSA) * Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN)Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, clinical data from its global INNO2VATE Phase 3 program, which demonstrated the efficacy and cardiovascular safety of vadadustat for the treatment of anemia due to chronic kidney disease, or CKD, in adult patients on dialysis.Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for the treatment of anemia due to CKD.The stock rose 7.32% to $3.52 in after-hours trading.Gilead's Veklury Receives Full Approval For Treating Hospitalized COVID-19 Patients Gilead said the FDA approved its antiviral drug Veklury (remdesivir) for the treatment of adults and pediatric patients, 12 years of age and older and weighing at least 40 kg, with COVID-19 and requiring hospitalization. Veklury had previously received emergency use authorization from the FDA for treating COVID-19 patients.The drug, which is the only FDA-approved treatment for COVID-19, is now widely available in hospitals across the country, Gilead said.In after-hours trading, the stock rallied 7.1% to $64.98.Retrophin to Acquire Rare Metabolic Disorder Drug Company Orphan Technologies For Up to $517 million Retrophin Inc (NASDAQ: RTRX) announced a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharma focused on the development of product candidate OT-58 for the treatment of classical homocystinuria, for $90 million in cash.Orphan Technologies shareholders will also be eligible to receive up to $427 million in additional cash payments contingent upon the achievement of key milestones in the development and commercialization of OT-58.Retrophin said it will also pay a tiered mid-single digit royalty on future net sales of OT-58 in the US and Europe, and potentially make a milestone payment in the event a pediatric rare disease voucher is granted.OT-58 is a novel investigational enzyme replacement therapy being evaluated in Phase 1/2 development for the treatment of classical HCU, a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications, as well as developmental delay.The deal is anticipated to close in the fourth quarter of 2020.Kezar Life Sciences Gets Orphan Drug Designations For Drug to Treat Autoimmune Inflammatory Myopathies Kezar Life Sciences Inc (NASDAQ: KZR) said the FDA has granted orphan drug designations for KZR-616 for the treatment of polymyositis and dermatomyositis. Both orphan diseases are autoimmune inflammatory myopathies that are chronic and debilitating diseases characterized by marked morbidity and mortality.Offerings Milestone Pharmaceuticals Inc (NASDAQ: MIST) said it priced its previously announced underwritten public offering of 3.81 million of its shares at $5.25 per share. The prefunded warrants issued to certain investors in lieu thereof, to purchase common shares were priced at $5.24 per underlying share.The company expects the offering to close Oct. 27.The stock slipped 16.14% to $5.87 in after-hours trading.On The Radar Clinical Readouts Mustang Bio Inc (NASDAQ: MBIO), founded by Fortress Biotech (NASDAQ: FBIO), is scheduled to present at the Prostate Cancer Foundation's annual scientific retreat initial Phase 1 data on CAR-T cell therapy MB-105 in patients with PSCA-positive metastatic castration-resistant prostate cancer. The presentation is fixed for Oct. 23, at 2:50 pm.IPOs Foghorn Therapeutics, which is engaged in the development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, priced its initial public offering of 7.50 million shares of its common stock at $16.00 apiece. Foghorn's common stock will begin trading on the Nasdaq under the ticker symbol FHTX.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In 0M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat * The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.